Development of a new diagnostic method for urothelial carcinoma by detecting urinary microRNA using cell sorting system

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09404
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Kagoshima University
• Principal Investigator: ENOKIDA Hideki 鹿児島大学, 医歯学域医学系, 教授 (80347103)
• Co-Investigator(Kenkyū-buntansha): 吉野 裕史 鹿児島大学, 医歯学域医学系, 講師 (90642611) ; 鑪野 秀一 鹿児島大学, 医歯学域医学系, 准教授 (30624655) ; 坂口 大 鹿児島大学, 鹿児島大学病院, 医員 (70779008)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 尿路上皮癌 / 腫瘍マーカー / マイクロRNA

Outline of Final Research Achievements

Screening for miRNAs revealed that miR-200a and miR-191 were useful markers, and they were able to differentiate between cancers and non-cancers with an accuracy of 0.864 AUC. In an ancillary study, the expression and induction of the tumor-suppressive miR-99a-5p inhibited the proliferative, migratory and invasive capacity of bladder cancer cells and improved GEM sensitivity in Gemcitabine (GEM)-resistant strains. In addition, knockdown of SMARCD1, the target gene of miR-99a-5p, also suppressed the proliferative ability of cancer cells. Furthermore, it was shown that the induction of miR-99a-5p and the suppression of SMARCD1 contributed to cellular senescence through the induction of p21.

Free Research Field

泌尿器癌

Academic Significance and Societal Importance of the Research Achievements

現在、尿路上皮癌に対する腫瘍マーカー開発はアンメットニーズであるが、今回の知見により、将来的な「尿路上皮癌の診断キット」の開発への基礎データを取得することができたと考える。また臨床的に問題である尿路上皮癌の抗癌剤耐性の克服に向けて、miR-99a-5pを基点とする新たな耐性機序克服に関する知見の獲得ができ、今後の尿路上皮癌治療の発展に寄与できるものと考える。